Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Culine, S.
Right arrow Articles by Droz, J.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Culine, S.
Right arrow Articles by Droz, J.-P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:1523-1530, 2000
© 2000 European Society for Medical Oncology

review-article

Chemotherapy in advanced androgen-independent prostate cancer 1990–1999: A decade of progress?

S. Culine1, and J.-P. Droz2

1Department of Medicine, CRLC Val d'Aurelle Montpellier
2Department of Medicine, Centre Léon Bérard Lyon, France

Correspondence to: S. Culine, MD CRLC Val d'Aurelle 34298-Montpellier Cedex 5 France E-mail: stculine{at}valdorel.fnclcc.fr

Background and purpose: A great number of clinical research studies have been reported in the field of chemotherapy for advanced androgen-independent prostate cancer during the last ten years. The aims of the present review were to assess their impact on management of the disease and on survival of patients.

Methods: The review of full published reports was facilited by the use of a MEDLINE computer search.

Results: Clinical research studies have focused on defining guidelines for eligibility criteria and accurate endpoints for patients to be enrolled onto clinical trials and developing new agents or combination of drugs including estramustine phosphate. Any combination of current chemotherapy has no impact on overall survival of patients. Among drugs in development, only the promising activity observed with docetaxel deserves randomized trials to assess its impact on survival. The major innovative advance of the 90s is the demonstration of the impact of chemotherapy (mitoxantrone + prednisone) on quality of life as compared to prednisone alone. A greater and longer-lasting improvement in quality of life along with a concomitant decrease in costs was observed.

Conclusions: At the present time, chemotherapy should be considered as a palliative treatment in patients with symptomatic androgen-independent disease. The enrollment of patients into clinical trials dealing with quality of life as primary endpoint is strongly solicited. A standard methodology should be used in phase II trials with a primary goal of selection of agents which should progress to randomized trials using survival as an endpoint. Hopefully new specific strategies targeted to reverse the molecular changes that underlie prostate tumorigenesis should rapidly impact the multimodality management of AIPC in the third millenium.

androgen-independent prostate cancer, chemotherapy, metastatic prostate cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J.-S. Diallo, A. Aldejmah, A. F. Mouhim, B. Peant, M. A. Fahmy, I. H. Koumakpayi, K. Sircar, L. R. Begin, A.-M. Mes-Masson, and F. Saad
NOXA and PUMA Expression Add to Clinical Markers in Predicting Biochemical Recurrence of Prostate Cancer Patients in a Survival Tree Model
Clin. Cancer Res., December 1, 2007; 13(23): 7044 - 7052.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
B. Peant, J.-S. Diallo, L. Lessard, N. Delvoye, C. Le Page, F. Saad, and A.-M. Mes-Masson
Regulation of I{kappa}B Kinase {varepsilon} Expression by the Androgen Receptor and the Nuclear Factor-{kappa}B Transcription Factor in Prostate Cancer
Mol. Cancer Res., January 1, 2007; 5(1): 87 - 94.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. K. Kolluri, M. Corr, S. Y. James, M. Bernasconi, D. Lu, W. Liu, H. B. Cottam, L. M. Leoni, D. A. Carson, and X.-k. Zhang
The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis
PNAS, February 15, 2005; 102(7): 2525 - 2530.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. P. Abratt, D. Brune, M.-A. Dimopoulos, J. Kliment, J. Breza, F. P. Selvaggi, P. Beuzeboc, T. Demkow, and S. Oudard
Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer
Ann. Onc., November 1, 2004; 15(11): 1613 - 1621.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Liu, K. Oettel, G. Ripple, M. J. Staab, D. Horvath, D. Alberti, R. Arzoomanian, R. Marnocha, R. Bruskewitz, R. Mazess, et al.
Phase I Trial of 1{alpha}-Hydroxyvitamin D2 in Patients with Hormone Refractory Prostate Cancer
Clin. Cancer Res., September 1, 2002; 8(9): 2820 - 2827.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.